Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging CCR2 in Lung Inflammation
NCT03492762Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2018
- Primary completion
- Dec 2027
- Modality
- Positron Emission Tomography Imaging
- Countries
- 1
01
Overview
Phase 1, open-label trial of Cu-DOTA-ECL1i in interstitial lung disease (ILD), pulmonary fibrosis (PF) and pneumonitis (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Change of uptake of Cu-DOTA-ECL1i to lung fibrosis, Change of Cu-DOTA-ECL1i as measured by Positron emission tomography (PET) imaging of lung Standard uptake value (SUV) and Distribution Volume Ratio (DVR) at 2 months and 1 more. Started Feb 2018; status: recruiting.
02
Drugs
Cu-DOTA-ECL1i
03
Conditions
interstitial lung disease (ILD)pulmonary fibrosis (PF)pneumonitis
Beyond the preview
Go deeper on NCT03492762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492762.